ArticleJACC. Asia2026
Association Between Serum Atherogenic Index and Cardiovascular Disease in Early Adulthood: A Cohort Study.
Article in JACC. Asia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe atherogenic index of plasma (AIP), calculated as log(triglycerides/high-density lipoprotein cholesterol), is a novel marker of atherogenic risk, but its association with cardiovascular disease (CVD) and mortality in early adulthood remains unclear.
objectivesThis study aimed to investigate whether AIP independently predicts the risk of CVD (including stroke) and all-cause mortality in young adults.
methodsWe analyzed 64,416 participants aged 18-44 years without prior CVD from the Kailuan Study (2006-2016). AIP was calculated at baseline, and participants were categorized into quartiles. The primary outcomes were incident CVD, stroke, and all-cause mortality, ascertained through December 2023. Multivariable Cox models adjusted for traditional risk factors, lipids, renal function, and medication use were used to estimate HRs.
resultsOver a mean follow-up of 14.65 years (Q1-Q3: 10.60-16.90 years), 1,853 CVD events, 1,571 stroke events, and 1,332 cases of all-cause mortality occurred. After full adjustment, compared with the lowest AIP quartile (Q1), the HRs for CVD in Q2-Q4 were 1.16 (95% CI: 0.99-1.36), 1.29 (95% CI: 1.11-1.50), and 1.36 (95% CI: 1.17-1.59), respectively. Corresponding HRs for stroke were 1.14 (95% CI: 0.97-1.35), 1.21 (95% CI: 1.03-1.43), and 1.26 (95% CI: 1.07-1.49). No significant association was found between AIP and all-cause mortality after multivariable adjustment. Sensitivity and competing risk analyses supported the robustness of these findings.
conclusionsHigher AIP is independently associated with increased risks of CVD and stroke in young adults. AIP may serve as a useful biomarker for early cardiovascular risk stratification in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.